Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019

Gu, Baoxia; Shang, Xiaogai; Yan, Mengqing; Li, Xiao; Wang, Wei; Wang, Qi; Zhang, Cuilian

doi:10.1016/j.ygyno.2021.01.036

Cited by 169 publications

(117 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the association between metabolic syndrome and endometrial cancer in recent studies is limited to Western women ( 37 ). Considering that incidence and mortality rates of endometrial cancer have ethnic and geographic variations ( 38 ), large cohort studies are also required in Asian women. Therefore, we performed a comprehensive national population-based cohort study of Korean females.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome as a Risk Factor of Endometrial Cancer: A Nationwide Population-Based Cohort Study of 2.8 Million Women in South Korea

Wang

Seol

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundA positive relationship was reported between metabolic syndrome and the risk of endometrial cancer. Studies on the relationship between metabolic syndrome and endometrial cancer have been mainly conducted in post-menopausal women. We aimed to investigate the risk of endometrial cancer according to metabolic syndrome and menopausal status using the Korean nationwide population-based cohort.MethodsWe enrolled 2,824,107 adults (endometrial cancer group; N = 5,604 and control group; N= 2,818,503) from the Korean National Health Insurance Service checkup database from January 1 to December 31, 2009. The median follow-up duration was 8.37 years. Metabolic syndrome was diagnosed as having at least three of the following five components: abdominal obesity, hypertriglyceridemia, low levels of high-density lipoprotein cholesterol, raised blood pressure, and hyperglycemia. Multivariate Cox proportional hazard models were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) to estimate endometrial cancer risk.ResultsThe endometrial cancer risk was higher in the metabolic syndrome group than that in the non-metabolic syndrome group (HR, 1.362; 95% CI, 1.281–1.449). The association between metabolic syndrome and endometrial cancer risk was significant in the premenopausal subgroup (HR, 1.543; 95% CI, 1.39–1.713) and postmenopausal subgroup (HR, 1.306; 95% CI, 1.213–1.407). The incidence of endometrial cancer was more closely related to metabolic syndrome components in the pre-menopausal subgroup than those in the post-menopausal subgroup (for waist circumference, blood pressure, triglycerides and high-density lipoprotein cholesterol, all p for interaction <0.0001 respectively, and for fasting blood glucose, p for interaction 0.0188). The incidence of endometrial cancer positively correlated with the number of metabolic syndrome components (log-rank p <0.0001).ConclusionOur large population-based cohort study in Korean women suggests that metabolic syndrome and its accumulated components may be risk factors for endometrial cancer, particularly in the pre-menopausal women.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic Syndrome as a Risk Factor of Endometrial Cancer: A Nationwide Population-Based Cohort Study of 2.8 Million Women in South Korea

Wang

Seol

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Globally, the incidence of endometrial cancer (EC) has increased significantly by 0.69% per year between 1990 and 2019, 1 and mortality continues to rise. Patients with advanced and recurrent EC represent a major therapeutic challenge, with 5-year overall survival rates of only 17% in patients with distant disease.…”

Section: Introductionmentioning

confidence: 99%

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer

2021

View full text Add to dashboard Cite

Following the discovery of the four molecular subtypes of endometrial cancer (EC) by The Cancer Genome Atlas (TCGA) in 2013, subsequent studies used surrogate markers to develop and validate a clinically relevant EC classification tool to recapitulate TCGA subtypes. Molecular classification combines focused sequencing ( POLE) and immunohistochemistry (mismatch repair and p53 proteins) to assign patients with EC to one of four molecular subtypes: POLEmut, MMRd, p53abn and NSMP (no specific molecular profile). Unlike histopathological evaluation, the molecular subtyping of EC offers an objective and reproducible classification system that has been shown to have prognostic value and therapeutic implications. It is an exciting time in EC care where we have moved beyond treatment based on histomorphology alone, and molecular classification will now finally allow assessment of treatment efficacy within biologically similar tumours. It is now recommended that molecular classification should be considered for all ECs, and should be performed routinely in all high grade tumours. It is also recommended to incorporate molecular classification into standard pathology reporting and treatment decision-making algorithms. In this review, we will discuss how the molecular classification of EC can be used to guide both conventional and targeted therapy in this new molecular era.

show abstract

“…Between 1990 and 2019, the global incidence of uterine corpus endometrial cancer (UCEC) increased significantly at a rate of 0.69% per year, accompanied by an increase in mortality [ 1 ]. Approximately 80% of patients with early UCEC have a good prognosis, with a 5-year overall survival rate of 95%, compared with 17% for patients with distant disease [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5

Qiu

Jie

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

As a molecular marker of the female reproductive system, Paired Box 8 is widely used in pathological diagnosis of gynecological tumors, but it is not clear whether its expression level is related to the development of uterine corpus endometrial carcinoma and molecular subtype classifications. Here, we show that PAX8 is up-regulated in TP53 mutation category of UCEC, which is result from the low methylation level of PAX8 in UCEC. We have identified that genes connected to ribosome, lysosome, ribosome biogenesis and cell cycle as PAX8 targets and demonstrate that modulation of the PAX8-DDX5 interaction influences c-MYC related cell cycle and cell growth. Our work defines DDX5 as a critical PAX8 co-factor, places the PAX8-DDX5 interaction in biological context, and highlights PAX8 as a key point for development of novel anti-MYC therapies in TP53-mutation UCEC.

show abstract

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019

Cited by 169 publications

References 26 publications

Metabolic Syndrome as a Risk Factor of Endometrial Cancer: A Nationwide Population-Based Cohort Study of 2.8 Million Women in South Korea

Metabolic Syndrome as a Risk Factor of Endometrial Cancer: A Nationwide Population-Based Cohort Study of 2.8 Million Women in South Korea

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer

Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5

Contact Info

Product

Resources

About